NBE-Therapeutics

About:

NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.

Website: http://www.nbe-therapeutics.com

Top Investors: Boehringer Ingelheim, Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group

Description:

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Total Funding Amount:

$65.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Basel, Basel-Stadt, Switzerland

Founded Date:

2012-01-01

Contact Email:

info(AT)NBE-Therapeutics.com

Founders:

Ulf Grawunder

Number of Employees:

11-50

Last Funding Date:

2020-01-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai